 |
市場調查報告書
商品編碼
1816821
非小細胞肺癌的標靶治療市場:KOL的洞察KOL Insights - Non-Small Cell Lung Cancer - Targeted Therapies |
||||||
本報告深入分析了來自美國和歐洲的12位關鍵意見領袖的觀點，全面探討了非小細胞肺癌 (NSCLC) 標靶治療的前景。本報告深入探討了目前和未來的治療途徑，重點關注Tagrisso、Lybrevat和Enhertz等成熟和新興療法的作用。深入了解新製劑帶來的課題和機會、近期藥物審批的影響以及不斷發展的治療方案。透過探討酪胺酸激酶抑制劑、KRAS抑制劑和其他標靶藥物的專家觀點，本報告為NSCLC治療的未來發展方向提供了寶貴的見解。
關鍵問題解答
- 阿斯特捷利康的Tagrisso目前是如何應用的？
- Genmab/強生公司 Rybrevant 的現今與未來用途。
- Livelevant 的皮下製劑將如何影響其臨床應用？
- 對新型 EGFR 和 HER 酪胺酸激酶抑制劑的預期。
- Enhertz 在非小細胞肺癌 (NSCLC) 臨床實務中是如何應用的？
- 對 Datroway、Emrelis 和 Ensacove 等近期核准藥物的看法。
- 專家如何使用 ALK 抑制劑？他們認為哪種抑制劑比較可取？
- 正在研發的 KRAS 抑制劑在 NSCLC 治療中的潛力。
- 專家如何預測 MET 抑制劑、RET 抑制劑、ROS1 抑制劑和 BRAF 抑制劑將如何改變治療方案？
- 預計 NSCLC 標靶治療的格局在近期和中期內將如何變化？
領導品牌
|
|
與會專家名單
- 杜克大學醫學院助理教授兼腫瘤內科醫師美國
- Jeffrey A. Brown 和 Barbara Horowitz-Brown，美國羅德島州普羅維登斯市生命跨度癌症研究所副教授、胸腔腫瘤學主任兼轉化醫學教授
- 美國馬裡蘭州約翰霍普金斯醫學院胸腔腫瘤臨床研究計畫主任兼腫瘤學副教授
- 英國伯明罕伊麗莎白女王醫院臨床腫瘤顧問醫師
- 法國馬賽艾克斯-馬賽大學馬賽公立醫院教授兼主任
- 法國維爾瑞夫古斯塔夫‧魯西醫學院胸腔腫瘤學組長
研究方法：
"治療趨勢" 報告是世界頂尖關鍵意見領袖 (KOL) 就重點疾病領域當前和未來治療前景開展的合作研究計畫。我們的報告透過對關鍵產業領袖的深入訪談編寫而成。關鍵意見領袖 (KOL) 的甄選是基於嚴格的標準，包括全球知名度、臨床專業知識以及在其治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與關鍵意見領袖合作開發，並由行業專家進行同行評審，確保問題全面且與當前市場動態相關。每份報告發布後，我們會持續 12 個月的市場監測，及時提供關鍵意見領袖對重大新聞事件、市場變化和市場發展的更新。
我們的報告有何獨特之處？
FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供詳盡且可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，讓您全面了解市場動態。我們的報告涵蓋 40 多個活躍疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入等領域問題的見解，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。
Explore the comprehensive landscape of targeted therapies in non-small cell lung cancer (NSCLC) with this detailed report, which analyzes insights from 12 key opinion leaders across the US and Europe. This report delves into the current and future treatment pathways, focusing on the role of established and novel therapies such as Tagrisso, Rybrevant, and Enhertu. Gain a deeper understanding of the challenges and opportunities presented by new formulations, the impact of recent drug approvals, and the evolving treatment algorithms. By examining expert perspectives on tyrosine kinase inhibitors, KRAS inhibitors, and other targeted agents, the report provides valuable insights into the future directions of NSCLC treatment.
Key Questions Answered:
- How is AstraZeneca's Tagrisso currently used, and how might its use evolve with ongoing trials?
- What are the current and future uses of Genmab/Johnson & Johnson's Rybrevant?
- What impact will the subcutaneous formulation of Rybrevant have on its clinical use?
- What are the expectations for novel EGFR and HER tyrosine kinase inhibitors?
- How is Enhertu utilized in clinical practice for NSCLC?
- What are the views on recent approvals like Datroway, Emrelis, and Ensacove?
- How do experts use ALK inhibitors, and which are preferred?
- What is the potential of pipeline KRAS inhibitors in NSCLC treatment?
- How do specialists expect the MET, RET, ROS1, and BRAF inhibitors to change treatment algorithms?
- How is the targeted treatment landscape for NSCLC expected to evolve in the near-to-medium term?
Key Brands:
|
|
Partial List of Participating Experts:
- Assistant Professor of Medicine and Medical Oncologist, Duke University, US
- Jeffrey A. Brown and Barbara Horovitz Brown Associate, Professor of Translational Medicine, Director of Thoracic Oncology at the Lifespan Cancer Institute, in Providence, RI, US
- Director of the Thoracic Cancer Clinical Research Program and Associate Professor of Oncology at Johns Hopkins Medicine, MD, US
- Consultant Clinical Oncologist, Queen Elizabeth Hospital Birmingham, UK
- Professor and head of department, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France
- Head of the Thoracic Cancer Group in the Department of Medicine at Gustave Roussy, Villejuif, France
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
非小細胞肺癌(NSCLC)的全球市場，規模，佔有率，趨勢，產業分析報告:類別，不同治療，各流通管道，各地區 - 市場預測，2025年～2034年
全球B型進行性纖維肉瘤轉移性非小細胞肺癌市場（依國家及地區）分析與預測（2025-2035）
非小細胞肺癌治療市場，按療法、按配銷通路、按癌症類型、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測
非小細胞肺癌治療市場規模、佔有率、趨勢分析報告：按類型、治療方法、分銷管道、地區和細分市場預測，2025 年至 2030 年
非小細胞肺癌市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按治療、按藥物類別、按最終用戶、按地區和競爭進行細分，2020-2030 年預測
非小細胞肺癌市場按類型、治療、最終用戶和地區分類
非小細胞肺癌市場規模、佔有率、成長分析、按類型、按治療方法、按最終用途行業、按地區 - 行業預測，2025-2032 年
非小細胞肺癌市場：KOL 洞察
非小細胞肺癌治療市場：按癌症類型、藥物類別、分銷管道分類 - 2025-2030 年全球預測
全球非小細胞肺癌市場：按類型、治療類型、藥物類別、通路和地區劃分的評估、機會和預測（2016-2030）